OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Pharmacology & Therapeutics is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Longitudinal Model‐Based Meta‐Analysis of Lung Function Response to Support Phase III Study Design in Chinese Patients With Asthma	475
More Than Pharmacokinetics: Transporters in Clinical Pharmacology	277
Sodium Bicarbonate Prescription and Extracellular Volume Increase: Real‐world Data Results from the AlcalUN Study	221
ICH S7B In Vitro Assays Do Not Address Mechanisms of QT_C Prolongation for Peptides and Proteins – Data in Support of Not Needing Dedicated QT_C Studies	188
When Can We Rely on Real‐World Evidence to Evaluate New Medical Treatments?	174
Estimating Culprit Drugs for Adverse Drug Reactions Based on Bayesian Inference	123
The Efficacy, Effectiveness, and Efficiency of Integrated QTc Assessment: Rationalizing Approaches to New Drug Modalities	108
Neurodegenerative Diseases: The Value of Early Predictive End Points	107
Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation	102
Enhancing External Control Arm Analyses through Data Calibration and Hybrid Designs	99
Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination	88
Issue Information	86
Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov	82
Pharmacogenomic Prescribing Guidelines: Are They Always Useful?	82
Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling	80
Protecting the Kidney: The Unexpected Logic of Inhibiting a Glucose Transporter	69
A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization	67
Nicotine Metabolite Ratio Decreases After Switching Off Efavirenz‐Based Therapy in People With HIV Who Smoke	62
Reply to “Questioning Bayesian Inference‐Based Models for Estimating Culprit Drugs for Adverse Drug Reactions”	61
In This Issue	59
ASCPT News	58
In This Issue	56
How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example	55
Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population	54
In this Issue	53

Progress in Clinical Pharmacology in China: A Randomized Controlled Study to Advance Genotype‐Guided Precision Medicine	49
Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors	49
Reply to “Interpretation of Pharmacovigilance Disproportionality Analyses”	47
Infection Risk Associated with High‐Efficacy Disease‐Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study	46
	46
French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten	46
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease	46
Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies	45
The Broader Context of Liquid Biopsy in Absorption, Distribution, Metabolism, and Elimination	44
A Biological Basis for Pharmacokinetics: The Remote Sensing and Signaling Theory	44
Machine Learning‐Led Optimization of Combination Therapy: Confronting the Public Health Threat of Extensively Drug Resistant Gram‐Negative Bacteria	44
Using Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities	43
Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use Authorization	41
Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned	39